EYE
Nova EYE Medical Limited
🇦🇺 ASX
🩺 HEALTH CARE
👑 Overview
📈 Performance
💰 Dividends
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-10.24%
Annual Growth
5 years average annual growth
💰
34.62%
Annual dividend yield
Based on the most recent dividend
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
5
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Nova Eye Medical Ltd. engages in developing suite of novel ophthalmic treatment technologies. The company is headquartered in Adelaide, South Australia. The firm operates through three segments: AlphaRET, and Glaucoma surgical devices. The Company’s AlphaRET segment is responsible for the commercialization of the 2RT ophthalmic laser, which is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD). 2RT is a patented nano-pulse laser device that rejuvenates retinal structures compromised by AMD. The Glaucoma Surgical Devices segment includes the designing, manufacturing, marketing, and sale of the iTrack, iTrack Advance and the Molteno3 glaucoma surgical device. The Molteno3 glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma.
📈 Performance
Price History
-6.37%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💰 Dividends
Payouts
💰 Annual Dividend Yield*
34.62%
💰 Annual Dividend Earnings Per $1,000 invested**
$346.15
💰 Most Recent Dividend Franked Percentage Estimate
100.00%
💰 Average Dividend Franked Percentage Estimate
100.00 %
💰 Dividend reinvestment
* Based on the most recent dividend
** Calculated by multiplying the most recent dividend yield by $1,000
Estimate your dividend
If you held
$
of EYE, your last dividend payment(s) would have been:
$ 2,488.48
on Wed Jul 29 2020
*Disclaimer: The information provided in this calculator is only a model to show you how long you need to invest for to achieve your goal, based on several factors, including past performance which is not an indicator of future performance. It is not a prediction and relies on assumptions, such as interest rates, that may vary and change the actual outcome. The results shown are only estimates and are not intended to be relied on when making a financial decision. Consider whether to get advice from a licensed financial adviser before making any financial decision.
Dividend History
1Y
5Y
10Y
Graph
Table
Year
Yearly Dividend Earnings Per Share
Franking Estimate
2024
$0.00
0.00%
2023
$0.00
0.00%
2022
$0.00
0.00%
2021
$0.00
0.00%
2020
$0.14
100.00%
2019
$0.00
0.00%
2018
$0.00
0.00%
2017
$0.00
0.00%
2016
$0.00
0.00%
2015
$0.00
0.00%
💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.15
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in EYE
5
📊 Total Capital Earnings
$656.78
🔃 Average investment frequency
10 weeks
💵 Average investment amount
$5,221
⏰ Last time a customer invested in EYE
79 days
EYE investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
33%
50k - 100k
50%
Less than 50k
👶 Age of investors
18 - 25
40%
26 - 34
20%
35 - 90
40%
🙋 Legal gender of investors
Female
Male
100%
Pearlers who invest in EYE also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
4.35%
📊 Share price
$104.33 AUD
⛳️ DIVERSIFIED
🧱 MATERIALS
💸 FINANCIALS
PYC Therapeutics Ltd. is a drug-development company, which provides a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The firm's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.
🙌 Performance (5Yr p.a)
48.36%
📊 Share price
$0.19 AUD
📈 HIGH PRICE GROWTH
🧬 BIOTECHNOLOGY
AVITA Medical, Inc., through its subsidiaries, engages in the development and commercialization of a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs. The company is headquartered in Valencia California, California and currently employs 207 full-time employees. The company went IPO on 2012-03-18. The firm is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
🙌 Performance (5Yr p.a)
116.70%
📊 Share price
$3.93 AUD
🧬 BIOTECHNOLOGY
NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.
🙌 Performance (5Yr p.a)
25.73%
📊 Share price
$47.45 AUD
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
Want more shares? Try these...
Euroz Hartleys Group Ltd. engages in the business of financial solutions. The company is headquartered in Perth, Western Australia. The firm provides a range of financial services from stockbroking to corporate finance, investing, funds management and wealth management. The Company’s segments include private wealth, wholesale, funds management, and others. The private segment includes private wealth advisers who work with high net wealth individuals, companies, SMSF and other clients. The Private wealth advisers provide investment offering of stockbroking and corporate services for clients. The Wholesale segment refers to the institutional dealing, research and corporate finance team who work with companies and other institutional clients. The Fund Management segment offers funds management services. The company provides a range of corporate finance, stockbroking, wealth management, institutional sales and targeted research services. Its subsidiaries include Euroz Hartleys Limited and Westoz Funds Management Pty Ltd.
🙌 Performance (5Yr p.a)
-4.18%
📊 Share price
$0.83 AUD
💸 FINANCIALS
EZZ Life Science Holdings Ltd. is a genomic life science company, which engages in the business of formulating, producing, marketing, and selling branded health and wellbeing products to retailers and consumers domestically and internationally. The company is headquartered in Sydney, New South Wales. The company went IPO on 2021-03-03. The firm is engaged in research and development in genomics and precision nutrition with a focus on four human health challenges, including genetic longevity, human papillomavirus (HPV), helicobacter pylori, and weight management. The company formulates, produces, markets and distributes health supplements under the brand of EZZ to retailers and consumers domestically and internationally. The firm is also a wholesale distributor of skin care products under the EAORON brand in Australia and New Zealand to pharmacies, supermarkets and specialist retailers. Its products under the EZZ brand include EZZ Hair Growth Spray, EZZ Hair Scrub, EZZ Hair Mask, EZZ Anti-frizz Hair Spray, EZZ Biotic Engastro Capsule, EZZ Coffee Jelly and EZZ Iron Jelly. The EZZ products cover market segments, including vitamin and dietary supplements, sports nutrition, herbal/ traditional and pediatric consumer health products.
📊 Share price
$2.61 AUD
🔭 LIFE SCIENCES TOOLS & SERVICES
Excite Technology Services Ltd. engages in the development and commercialization of intellectual property primarily in the field of data security technology. The company is headquartered in North Sydney, New South Wales. The company went IPO on 2007-01-03. The Company, through its wholly owned subsidiaries and trading as Excite Cyber, provides focused managed cyber security, cloud, and information technology (IT) services. Its subsidiaries include Brace168 Pty Ltd, Virtual Information Technology Pty Ltd (VIT), ExciteIT Pty Ltd, CipherPoint Software, Inc, Cipherpoint Australia Pty Limited, Cipherpoint GmbH, and others. Brace168 Pty Limited (Brace168) is engaged in the provision of cybersecurity services predominantly in NSW. Virtual Information Technology Pty Ltd (VIT) is engaged in the provision of cybersecurity services predominantly in Tasmania. VIT provides a range of services, including Digital Forensics and Incident Response (DFIR), Identity Protection and Consulting services. ExciteIT Pty Ltd focuses on IT managed services across Australia.
🙌 Performance (5Yr p.a)
-19.17%
📊 Share price
$0.01 AUD
🤖 TECHNOLOGY
